These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 12383667)

  • 1. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.
    Equi A; Balfour-Lynn IM; Bush A; Rosenthal M
    Lancet; 2002 Sep; 360(9338):978-84. PubMed ID: 12383667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
    Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
    Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
    Stick SM; Foti A; Ware RS; Tiddens HAWM; Clements BS; Armstrong DS; Selvadurai H; Tai A; Cooper PJ; Byrnes CA; Belessis Y; Wainwright C; Jaffe A; Robinson P; Saiman L; Sly PD;
    Lancet Respir Med; 2022 Aug; 10(8):776-784. PubMed ID: 35662406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.
    Balfour-Lynn IM; Klein NJ; Dinwiddie R
    Arch Dis Child; 1997 Aug; 77(2):124-30. PubMed ID: 9301350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
    JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
    Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
    Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    Kobbernagel HE; Buchvald FF; Haarman EG; Casaulta C; Collins SA; Hogg C; Kuehni CE; Lucas JS; Moser CE; Quittner AL; Raidt J; Rosthøj S; Sørensen AL; Thomsen K; Werner C; Omran H; Nielsen KG
    Lancet Respir Med; 2020 May; 8(5):493-505. PubMed ID: 32380069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.
    Wolter J; Seeney S; Bell S; Bowler S; Masel P; McCormack J
    Thorax; 2002 Mar; 57(3):212-6. PubMed ID: 11867823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily versus weekly azithromycin in cystic fibrosis patients.
    McCormack J; Bell S; Senini S; Walmsley K; Patel K; Wainwright C; Serisier D; Harris M; Bowler S
    Eur Respir J; 2007 Sep; 30(3):487-95. PubMed ID: 17537764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the effects of combining azithromycin with inhaled tobramycin for
    Nichols DP; Singh PK; Baines A; Caverly LJ; Chmiel JF; GIbson RL; Lascano J; Morgan SJ; Retsch-Bogart G; Saiman L; Sadeghi H; Billings JL; Heltshe SL; Kirby S; Kong A; Nick JA; Mayer-Hamblett N;
    Thorax; 2022 Jun; 77(6):581-588. PubMed ID: 34706982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia.
    Kobbernagel HE; Buchvald FF; Haarman EG; Casaulta C; Collins SA; Hogg C; Kuehni CE; Lucas JS; Omran H; Quittner AL; Werner C; Nielsen KG
    BMC Pulm Med; 2016 Jul; 16(1):104. PubMed ID: 27450411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.
    Ordoñez CL; Stulbarg M; Grundland H; Liu JT; Boushey HA
    Pediatr Pulmonol; 2001 Jul; 32(1):29-37. PubMed ID: 11416873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.